If You’re Biogen and Own the First Alzheimer’s Treatment to Win FDA Approval in 20 Years,(2) Your Stock Can Spike 60+% In a Day(1)

But We’ve Unearthed a Company With A Transformative Treatment That Could Shatter That…Alpha Cognition Inc. (TSXV:ACOG.V)

Research by Sam Roberts of LW Media
September 30, 2021

It’s been quite a year for biotech and healthcare innovation.

While mRNA vaccines and the current health disaster get most of the attention, there’s a silent revolution going on behind the scenes. A revolution that’s so generationally massive that we could finally be on the verge of curing one of the most debilitating conditions known to mankind- Alzheimer’s.

Both patients and physicians have long been clamoring for effective treatments. The current ones are simply not working. This progressive neurodegenerative disease still has no cure, and it’s devastating for all involved.

Investors are always looking for stocks that show potential in solving this problem. Because of the desperate need for cutting-edge treatments, when there’s any semblance of progress, the stock can skyrocket in a matter of days, hours, minutes, and even seconds.

Look at Biogen, for example. This is a large-cap pharma stock with a 42.56B market cap as of September 29, 2021.(3) On the surface, you’d think this isn’t the type of stock that has a massive one-day spike the same way that small-cap biotech stocks can have.

Well, when word gets out that you may have the first Alzheimer’s treatment to win FDA approval in nearly 20 years,(2) you can throw those assumptions out the window.

After Biogen’s Alzheimer’s dr-ug Aduhelm won accelerated FDA approval, the stock surged as much as 63.83% on June 7, 2021, from a low of $286.00 to a high of $468.55.(1)

In one day.

Eli Lilly, another big-time pharma company with potential Alzheimer’s treatments, jumped by more than 10% that same week after the FDA approval for Aduhelm was announced.(4)

Other pharma companies with a focus on Alzheimer’s treatments have seen their stocks show eye-popping moves too.

  • Cassava Sciences- Was trading at only $6.70 on Dec 29, 2020. As of Sep 29, 2021, it was trading at $62.14- an 827.46% move in a matter of months. (5)
  • INmune Bio- Traded as low as $7.28 on Oct 30, 2020, trading at $19.22 as of Sep 29, 2021- a 164.01% move.(6)
  • Annovis Bio- Was only trading at roughly $4.14 on Nov 02, 2020. As of Sep 29, 2021, it was sitting at $31.34- a stunning 657% move.(7)

Maxim analyst Jason McCarthy said the approval of Biogen’s dr-ug, the flurry of activity in the space, and growing interest merits a “recalibration” of promising AD players’ valuations.(8)

Yet while the above examples back up McCarthy’s claims, we may have uncovered someone with an upside potential that could crush them all: Alpha Cognition Inc. (TSXV:ACOG.V).

Alpha Cognition Inc. (TSXV:ACOG.V) is a late-stage biopharmaceutical company focused on neurodegenerative diseases. But this isn’t just some biotech company with experimental treatments that hopefully work. It has a large addressable market, a potentially accelerated path to FDA approval, a differentiated product suite, and efficient management.

Not to mention, according to data from Finbox, the ACOG.V stock’s latest twelve months upside (analyst target) could be an astounding 159.3% as of Sep 30, 2021.(12)

Overall, this could be one of the most cutting-edge companies transforming medicine that we’ve ever seen.

Read on and learn why. Your mind will be blown just as much as ours was.

Reason #1: A Large Established Market With Underserved Patients and Frustrated Physicians

Let’s cut to the chase. Alzheimer’s is horrendous, heartbreaking, and excruciating. It is characterized by the loss of cholinergic neurons in the brain. Decreased acetylcholine levels and loss of receptors negatively impact learning, memory, and function.

Basically, suppose you’ve ever had a family member suffer from it. In that case, you know exactly what I’m talking about and how soul-crushing it is to have a parent or grandparent, or aunt or uncle, not even know you.

The fact that there’s still no satisfactory cure for this progressive neurodegenerative condition is despicable. Especially when you consider how many people it affects.

According to the Alzheimer’s Association, this disease impacts an estimated 6 million people in the U.S. alone, with 1 person diagnosed every 65 seconds.(9)

Treatments are only getting more expensive too. The estimated healthcare cost for Alzheimer’s and other dementias is roughly $355 Billion per year. It is expected to increase to more than $1.1 Trillion annually by 2050.(9)

Furthermore, 8 out of 10 patients start on an ACHEI as standard first-line therapy, and only 4.5 out of 10 remain on therapy at 12 months due to the side-effects.(10)

Do the math. 30% discontinue treatment by month 4, and 45% discontinue treatment by the end of 1 year.(10)

Luckily, Alpha Cognition Inc. (TSXV:ACOG.V) and its ALPHA-1062 dr-ug candidate could have an answer to all of these problems. This potential best-in-class treatment is designed to optimize efficacious dose, minimize treatment-limiting side-effects and improve long-term outcomes.

Reason #2: A Dr-ug With An Accelerated Path to FDA Approval That Can Keep Patients Out of Long-Term Care Without Side Effects

Let’s talk a bit more about Alpha Cognition’s ALPHA-1062. This is a patented potential New Chemical Entity for the treatment of mild-to-moderate Alzheimer’s Dementia.

It could be a potential best-in-class treatment designed to optimize efficacious dose, minimize treatment-limiting side-effects and improve long-term outcomes.

It is a pro-dr-ug of Galantamine with decreased side effects and increased bioavailability. The formation of the benzoyl ester eliminates AChE inhibition. The gluconate salt increases solubility.

Galantamine, the metabolite, is then free to circulate with greater bioavailability. ALPHA-1062 is subject to 1st pass effect, cleaving the benzoyl ester, resulting in the release of Galantamine (active moiety).

It is then absorbed in the small intestine as an inactive compound with minimal or no side effects.

Compare this to the traditional ACHEI treatments with their activity in the GI Nervous System overstimulating local neurons resulting in side effects.

Exploratory studies have also demonstrated an improved gastrointestinal side effect profile.

Not to mention, long-term usage of Galantamine is associated with delayed placement in long-term care. 80% of galantamine-treated patients were living independently versus 30% of untreated patients at 36 months.(10) With each year of treatment with Galantamine, the risk of nursing home admission was reduced by a stunning 31%.(10)


  • In an April 2021 Neurology publication, 39,196 Alzheimer/Mixed Dementia patients (Swedish Dementia Registry) were evaluated between 2007-2017 with a 5yrs follow-up.
  • Galantamine was associated with a lower risk of death (P-value <0.001) compared to untreated patients. It was also superior to donepezil and rivastigmine-treated patients.
  • Galantamine had the most potent effect on cognitive decline and was the only AChEI demonstrating a statistically significant reduction in the risk of developing severe dementia (P-value 0.05) compared to donepezil (P-value 0.13) and rivastigmine (P-value 0.24).
  • Donepezil, having the highest number of patients studied, could not show more significant benefit than Galantamine.

Reason #3: De-Risked With Patents Extending To 2040

Here’s what could honestly give Alpha Cognition Inc. (TSXV:ACOG.V) an edge towards accelerated FDA approval. ALPHA-1062 is a De-risked 505(b)(2) new dr-ug application (NDA) with a high probability of success.(10)

For this NDA, a single bioequivalence study is required. Already, ALPHA-1062’s pilot studies more than support the requirements.

With patents extending to 2040, a pivotal trial initiation by Q3 2021, a safety and tolerability trial expected to be initiated by H1 2022, and NDA Submission by Q3 2022, watch out.(10)

Reason #4: Diverse Product Suite Addressing Areas of High Unmet Medical Needs

Alpha’s early-stage pipeline provides additional opportunities for value creation. Outside of treatment of mild-to-moderate Alzheimer’s Dementia, ALPHA-1062 + Memantine could be very promising in the treatment of moderate-to-severe Alzheimer’s dementia as well.

Memantine has been indicated for moderate-to-severe Alzheimer’s dementia and is often used in combination with an ACHEI. Roughly 7.7 million Rx have been written for memantine-containing products. There is also a 505(b)2 regulatory path for approval of a combination product like this. Look at NAMZARIC, for instance.(10)

ALPHA-1062’s intranasal delivery could also show potential in treating mild Traumatic Brain Injury. A preclinical study is ongoing, with Phase 1a and 1b intranasal studies complete. The indicators already look vastly promising.

There’s also a promising candidate to treat ALS called ALPHA-0602. Already granted Orphan Dr-ug status by the U.S. FDA in 2020,(10) this just gives the company yet another avenue to treat an unmet medical need without a cure.

It’s in the midst of ongoing preclinical development to identify optimal constructs with top-line results expected by Q1 2022.(10)

Reason #5: A Tightly Held Stock That’s Shown Explosive Moves And Upside Potential

If you want a company showing high-growth possibility, you want that company to be tightly held with a stock showing breakout potential. If analysts give the stock a robust upside target, that’s icing on the cake.

Alpha Cognition Inc. (TSXV:ACOG.V) has all that and then some.

The stock has only been trading since Mar 31, 2021, and has seen some jaw-dropping breakouts. For instance, on Jun 24, 2021, the stock traded as low as $0.750 a share. It then promptly broke out by as much as 232% to reach its highest level to date of $2.49 on Sep 14, 2021.(11) So while the stock has since pulled back, it could touch these levels again if everything goes according to plan and as the movement to find an Alzheimer’s cure gains steam. Already, the stock has moved 12% in a matter of days, between Sep 27-29, 2021.(11)

According to Yahoo! Finance, the stock is also tightly held, with a float of just about 31.84M and 31.99% of shares held by insiders.(12) On any inkling of good news, and believe me, the potential catalysts are mounting for the company, this stock could explosively pop in a short amount of time. Its 232% rally between Jun 24, 2021, and Sep 14, 2021, reflects this.(11)

Is it any wonder why then, according to data from Finbox that the ACOG.V stock’s latest twelve months upside (analyst target) could be an astounding 159.3%?(12)

Biogen who?

The bottom line is this…

When you catch an innovative pharma stock meeting an unmet medical need at the right time, the moves can be life-changing.

We’ve seen it in the recent past with biotech stocks like Moderna. But specifically, when it comes to companies focusing on Alzheimer’s, some of the breakouts have been stunning.

When we unearthed Alpha Cognition Inc. (TSXV:ACOG.V), the possibilities excited us to no end. It’s tightly held, the stock has moved explosively, and it’s well on track to have potential full FDA approval for a transformative Alzheimer’s treatment within the next 2 years.

After seeing what Biogen did in one day after receiving FDA approval for an Alzheimer’s dr-ug, can you imagine the potential?

Analysts are certainly hip to it based on that potential 159.3% twelve months upside (analyst target), according to Finbox.(12)

If you don’t monitor Alpha Cognition Inc. (TSXV:ACOG.V) closely over the short-term and long-term, you may greatly regret it one day.


Source List

Legal Disclaimer

This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.


Pursuant to an agreement between TD Media LLC and Bello Capital Partners, TD Media LLC has been hired for a period beginning on 10/18/2021 and ending on 10/19/2021 to publicly disseminate information about (ACOGF:US) (ACOG:CA) via digital communications. We have been paid twenty five thousand dollars USD via bank wire transfer.

Pursuant to an agreement between TD Media LLC and Bello Capital Partners, TD Media LLC has been hired for a period beginning on 10/20/2021 and ending on 10/29/2021 to publicly disseminate information about (ACOGF:US) (ACOG:CA) via digital communications. We have been paid an additional seventy thousand dollars USD via bank wire transfer. We own zero shares of (ACOGF:US) (ACOG:CA). To date we have been paid ninety five thousand dollars USD via bank wire transfer. To disseminate information about (ACOGF:US) (ACOG:CA) via digital communications.


Privacy Policy